Saison Bio and ImmunoChina Join Forces to Usher in a New Era of Cell Therapy

CellStore, a pioneer in the new generation of biobanking cryopreservation technology—"Controlled Ice Cryopreservation"—is an innovative biotechnology company that has begun to make its mark in the industry. The company has achieved remarkable success in precise cryopreservation of samples, high-quality cryopreservation of challenging samples, and maintaining the fidelity and viability of biological samples. Continuously developing advanced cryopreservation products, CellStore offers a wide range of precise cryopreservation solutions. Currently, its product offerings cover multiple specialized fields, including the cryopreservation of various human-derived cells, germ cells in assisted reproductive technology, and the preservation of viable biological tissues. It is committed to building a world-leading platform for cryopreservation technologies of biological samples, providing global customers with safe, efficient, and superior biobanking products and services.

Yimiao Shenzhou, as a company that has achieved repeated successes in the field of gene and cell drug research and development, always adheres to the mission of "making cancer no longer an incurable disease" and is committed to applying innovative gene and cell drug technologies to the treatment of malignant tumors. Yimiao Shenzhou has set a new industry benchmark with its self-developed next-generation CAR-T technology. This technology achieves serum-free production throughout the entire process, high production success rates, and long-lasting efficacy in vivo, significantly improving the effectiveness and safety of the products. The company has developed several CAR-T drugs for the treatment of advanced cancer and has obtained multiple IND approvals. On November 27 this year, Yimiao Shenzhou's marketing authorization application for IM19 CAR-T Cell Injection for the treatment of relapsed or refractory diffuse large B-cell lymphoma was accepted by the National Medical Products Administration. In addition, Yimiao Shenzhou also owns a GMP production base compliant with relevant regulations in China, the United States, and the European Union, and has a one-stop CAR-T drug R&D, production, and quality system, laying a solid foundation for the commercial production of the drugs.

Under the promotion and impetus of this cooperation agreement, both parties will fully leverage their respective advantageous resources in the cell therapy field to jointly advance the clinical trials, production, and commercialization of cell therapy drugs. CellStore Biotechnology Co., Ltd. will provide its unique ice-controlled cryopreservation technology to ensure the safety and efficacy of cell therapy drugs during the production and transportation processes; meanwhile, Beijing Yimiaoshenzhou Medical Technology Co., Ltd. will utilize its extensive experience in the research and development of cell therapy drugs to accelerate the new drug development process and create more efficient and safer biotherapeutic products to meet the needs of a wide range of patients and drive the continuous development of the biotech industry.

"CellStore has always been committed to providing the safest and most efficient biobanking solutions. We believe that our collaboration with Beijing Yimiaoshenzhou Medical Technology Co., Ltd. will greatly advance the research, development, and application of cell therapy technologies, offering patients more effective treatment options."

"Yimiao Shenzhou always adheres to a patient-centered approach, continuously exploring and innovating in cell therapy. The professional cryopreservation technology of CellStore will provide solid support for our R&D and production. We look forward to accelerating the launch of new drugs through this collaboration, benefiting more patients."

In the future, CellStore Biotechnology Co., Ltd. and Beijing Yimiaoshenzhou Medical Technology Co., Ltd. will continue to work hand in hand to jointly explore new technologies, new applications, new models, and new frontiers in the field of cell therapy. Both parties will continuously drive technological innovation and industry upgrading, providing more patients with safer, more effective, and more accessible cell therapy products. It is believed that in the near future, cell therapy will become the preferred treatment option for more cancer patients, bringing them the miracles of life and hope.